Summary.-The relationship of serum carcinoembryonic antigen (CEA) levels to tumour size and antigen content was studied in nude mice bearing well differentiated, mucinous human colonic -tumour xenografts. Blood samples were taken from normal nude mice and others bearing xenografts, whose size had been calculated from in vivo measurements; saline and KCI extracts were made of a proportion of these tumours. Sera and tissue extracts were assayed for CEA activity by double-antibody radioimmunoassay. Extracts were also made from the livers and spleens of tumourbearing and normal nude mice.
and tumour size or weight, or between serum CEA and tumour CEA concentrations or total CEA burden. The concentration of CEA in those tumours tested varied from 1 to 22 /Lg/g.
Our results confirm and extend the conclusions reached by others (Stragand et al., 1980) studying the significance of serum CEA levels with xenograft model systems. The complexity of factors contributing to circulating CEA is discussed in the light of our findings.
DURING RECENT YEARS much attention has been focused on the relationship between circulating carcinoembryonic antigen (CEA) levels and various aspects of colorectal tumour biology (e.g. size, degree of differentiation, extent of metastatic spread). However, it is difficult to draw many firm conclusions from the considerable volume of published data. Some studies have shown that circulating CEA levels may not be directly related to tumour size (Reynoso et al., 1972; Holyoke et al., 1972) although it must be said that measurement of tumour size in the patient is extremely difficult. A lack of correlation has also been reported between circulating CEA levels and the degree of tumour differentiation (Dhar et al., 1975; Bivins et al., 1975) or tumour CEA content (Gallo et al., 1977; Khoo et al., 1973; Goldenberg et al., 1976b; McClendon et al., 1977) .
Several authors, however, have suggested that circulating CEA levels more accurately reflect the general extent of disease (Dhar et al., 1975; Zamcheck et al., 1975; Breuer et al., 1980) and that this may, in part, be a result of the degree of necrosis and vascular invasion within the tumour (Bivins et al., 1975; Zamcheck et al., 1975; Breuer et al., 1980) . It is surprising, therefore, that very few studies have been published using in vivo model systems-especially colonic-tumour xenografts. One widely quoted study of nude mice bearing well differentiated colonic-tumour xenografts proposed that serum CEA levels were indeed directly proportional to tumour size (Miwa et al., 1976 (Miwa et al., , 1977 Kubota et al. 1978) . However, little reliance, if any, can be placed on this conclusion, given the low number of samples (5). Other authors mentioning a similar relationship have also based their findings on very low sample numbers (Mach et al., 1974) . In contrast, a much larger study (Stragand et al., 1980) , using nude mice bearing "LoVo" colonic-tumour xenografts, demonstrated no correlation between tumour size and serum CEA. Similar findings have been reported for immune-deprived mice bearing xenografts of breast carcinoma (Davies & Steel, 1978) . It has also been found that blood AFP levels in immune-deprived mice bearing human malignant teratoma xenografts did not correlate well with tumour size (Raghavan et al., 1980 (Looney et a., 1973) and weights estimated from previously constructed calibration curves. Estimated tumour weights ranged from 0-02 g to 7-20 g with a mean of 1-08 g.
Eleven of the 55 tumour-bearing mice and 5 control mice were killed by cervical dislocation after bleeding, and tumours, livers and spleens removed. All organs were weighed, and a small sample of each tumour fixed in 10% formalin for subsequent histological examination. Tumours were then reweighed. Whole tumour weights ranged from 0-16 to 7-14 g (mean 1-61 g).
Tissue samples were homogenized in physiological saline and the homogenates centrifuged at 75,000 g for 30 min. Supernatants were dialysed against twice-daily changes of tap water at 4°C for 72 h, and concentrated to 5 ml by ultrafiltration. Samples were centrifuged for a second time at 75,000 g, 30 min, and the supernatants stored at -20°C with 0 02% sodium azide, after recording their volumes. These samples were designated saline extracts.
Homogenate sediments produced by the first ultracentrifugation were washed once with physiological saline and extracted for 72 h with an excess of 3M KCI. Extracts were centrifuged, dialysed, concentrated, re-centrifuged and stored as above. These samples were designated KCI extracts.
CEA levels in tumour and normal-tissue extracts and serum samples were measured by double-antibody radioimmunoassay. CEA isolated from hepatic metastases of colonic tumours by perchloric acid extraction and purification on Sepharose 6B and Sephadex G-200 (Keep et al., 1978 ) (Preparation M12) was used as standard (8 doubling dilutions of 25 top standard 500 ng/ml CEA). The CEA preparation used as label was extracted as above and purified further on Con ASepharose (Keep et al., 1978) and designated CEA-2B. Jodination was carried out by a modification of the Chloramine T technique (Greenwood et al., 1963) yielding a specific activity of 179 ,uCi/ptg protein.
The primary antiserum (PkIG (D2)) was raised in a goat to CEA-2B, then absorbed with normal human plasma and perchloric acid extracts of normal human spleen, colon and liver in immunoabsorbent columns. The absorption was monitored by rocket immunoelectrophoresis of the absorbed antiserum against a 20mg protein/ml solution of each normal human tissue. The absence of rockets was taken to indicate lack of cross-reaction. Precipitation of the CEA-anti-CEA complexes was achieved with second antibody (BW402 horse anti-(goat + sheep)).
For the tumour and normal-tissue extracts (buffer-based system) 10 zero-antigen tubes (maximum binding of label) were set up with buffer (0-05M phosphate, pH 6, containing BSA (0.1% w/v) and EDTA (3.4 mM); 200 ,ul) , primary antiserum (dilution 1/4400; 50 [I) and CEA label (80,000 ct/min; 50 jul).
Into 10 nonspecific binding tubes were placed buffer (250 IlI) and label (50 pl) only. The standards, and samples at appropriate dilutions in buffer were set up in triplicate containing standard/sample (100 ,ul), buffer (100 ,tl), primary antiserum (50 ,ul) and label (50 ,u). Incubation was allowed to proceed for 16 h at 37°C and then second antibody (dilution 1/40; 50 plI) added. After a further incubation at 37°C for 8 h the bound fraction was obtained. Filtration, counting and analysis was performed on the Kemtek 3000 automated radioimmunoassay system. Measurement of serum samples was essentially as described above, except that all samples (in triplicate) were assayed directly at dilution 1/4. Insufficient serum was available to assay neat serum in triplicate. Buffer (100 pl) was added to the samples and normal nude mouse serum (nu/nu) at dilution 1/4 (100 pl) added to the zero-antigen, nonspecific binding and standard tubes.
Doubling dilutions of each sample were measured to ensure a parallel response to the standard line. The interassay coefficient of variation was 13%. Since the sensitivity of the radioimmunoassay was 2-85 ng/ml and the serum samples were all measured at dilution 1/4, the lower cut-off point was set at a CEA value of 11L4 ng/ml. This was not taken to represent the upper limit of serum CEA in normal nude mice but rather as the lowTer limit of detection in the diluted serum samples, necessitated by our insistence upon triplicated assays.
Tumour samples fixed in formalin wNere embedded in paraffin wax and 5,UM sections cut and stained with haematoxylin and eosin by conventional methods.
RESULTS
The histological appearance of all tumour samples was typical of the xenograft line (as described in Materials and Methods).
All sera from control animals and 43 of the 55 sera from tumour bearers had CEA values < 11b4 ng/ml. The remaining 12 showed values ranging from 13-9 to 47-8 ng/ml (and tumour weights 0 22-7*14 g). No clear correlation was found between the serum CEA values and tumour size or weight (Fig. 2) (Dyce & Haverback, 1974; Sharkey et al., 1 977; Khoo et al., 1973; WVarner et al., 1973) and that differences may exist in regional CEA concentration within a single tumour (Wagener & Breuer, 1978) , previous work with single xenograft lines suggests that the concentration of antigen in these models varies little from tumour to tumour (Munjal & Goldenberg, 1976; Chao et al., 1974; Miwa et al., 1977 Miwa et al., , 1976 ) a 4-fold variation being the highest quoted (Carrel et al., 1976 (Goldenberg et al., 1976a) . The proportion of a tumour's cell population producing and excreting CEA clearly plays an important role. From in vitro studies, the highest cellular content and maximum production of CEA by colorectal-carcinoma cells is seen in the stationary or G phase of the cell cycle, whereas, conversely, exponentially growing cell populations have relatively low CEA content. However, release of CEA is not necessarily related to cellcycle phase (Drewinko & Yang, 1976 Cohen & Wrood, 1979) . Tumour CEA concentration and total CEA burden will therefore be heavily dependent upon the kinetics of cell cycling within individual tumours, although the rate of CEA release need not necessarily be proportional to tumour CEA concentration and total CEA burden. It has also been suggested that CEA may be released during or after cell death (Bivins et al., 1975; Davies & Steel, 1978; Breuer et al., 1980) ; if so, the cellloss rate of a tumour would also influence rate of CEA release. It is reasonable to suggest that levels of circulating CEA will also be affected by the relative partitioning of released CEA between the tumour interstitium, blood vascular space and gut lumen (for primary tumours (Molnar et al., 1976) ). Not surprising, therefore, is the finding that the degree of vascularization (Bivins et al., 1975; Sharkey et al., 1977; Zamcheck et al., 1975) and lymphatic invasion of tumours can be loosely related to plasma CEA levels. Finally, host metabolism and degradation of CEA will affect circulating levels. Clearance of circulating CEA is thought to be mediated primarily by the liver (Shuster et al., 1973; Primus et al., 1973a) , possibly by the hepatocytes. Thus depressed hepatic function may maintain circulating CEA at abnormally high levels, and the relative importance of CEA derived from normal gastrointestinal-tract cells may be increased (review by Loewenstein & Zamcheck, 1977) . Decreased plasma CEA clearance may also result from the presence of circulating immune complexes formed between CEA and autologous anti-CEA (Primus et al., 1973a (Primus et al., , 1974 at least in experimental systems, although the significance of this in the human is as yet undetermined.
Given this complex array of factors potentially influencing circulating CEA levels, it is perhaps not surprising that no simple relationship exists between serum CEA and tumour size, weight, CEA concentration or tumour CEA burden in our system. The xenografts used show marked individual variation in CEA content; the exact degree of vascular invasion and necrosis varies from tumour to tumour (as judged by histological examination of tumour sections) and other relevant features such as host response and cellcycle kinetic factors may vary from tumour to tumour, though we have not yet examined these. This is not to say that xenografts are inappropriate models for the study of CEA metabolism. It may be necessary for future studies of circulating CEA, and its relationship to aspects of tumour biology, to assess such features sequentially in individual xenograft-bearing animals, rather than across a population of such tumours.
